The expanded deal calls for multi-product drug substance manufacturing across six biologics programs at AGC Biologics’ Copenhagen site, encompassing process transfer, scale-up, validation, and commercial production.
The expanded deal calls for multi-product drug substance manufacturing across six biologics programs at AGC Biologics’ Copenhagen site, encompassing process transfer, scale-up, validation, and commercial production.